Minzasolmin Drug Asset Due Diligence Report 2026

This Minzasolmin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Minzasolmin can convert its Small molecule drug profile and α-synuclein biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Minzasolmin (query alias: Minzasolmin)
Modality / target	Small molecule drug; α-synuclein; α-synuclein inhibitors
Highest global status	Phase 2
Originator	Neuropore Therapies, Inc.
Active developers	UCB Biopharma SRL, Novartis Pharma AG, UCB SA

The MCP disease footprint includes Parkinson Disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05543252	Phase 2	Terminated	428	Change From Baseline in Dopamine Transporter Imaging, Measured by Single Photon Emission Computed Tomography (DaT-SPECT), Whole Striatum Specific Binding Ratio up to PD0055 EOT or ET (Corresponding to a Visit Between PD0055 Month 6 and Month 18 Inclusive)
NCT05845645	Phase 1	Completed	73	Maximum Plasma Concentration (Cmax) of UCB0599 in Part A
NCT04875962	Phase 1	Completed	31	Treatment-Emergent Adverse Avents (TEAEs) from Baseline to End of Study visit

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Dose-Blinded Extension Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of UCB0599 in Study Participants With Parkinson's Disease

Phase 2; n=428; evaluation: not stated. Reported fields: Change From Baseline in Dopamine Transporter Imaging, Measured by Single Photon Emission Computed Tomography (DaT-SPECT), Whole Striatum Specific Binding Ratio up to PD0055 EOT or ET (Corresponding to a Visit Between PD0055 Month 6 and Month 18 Inclusive)(Mean) = -0.370 specific binding ratio (Standard Deviation, 0.285); -; Change From Baseline in Dopamine Transporter Imaging, Measured by Single Photon Emission Computed Tomography (DaT-SPECT), Whole Striatum Specific Binding Ratio up to PD0055 EOT or ET (Corresponding to a Visit Between PD0055 Month 6 and Month 18 Inclusive)(Mean) = -0.426 specific binding ratio (Standard Deviation, 0.322)

An Open-Label, Randomized Study to Evaluate the Relative Bioavailability of a New Tablet Formulation of Minzasolmin and the Potential Effect of Food on the Pharmacokinetics of Minzasolmin in Healthy Participants

Phase 1; n=18; evaluation: not stated. Reported fields: Area Under the Plasma Concentration-time Curve From Time 0 to t (AUC[0-t]) for Minzasolmin(Geometric Mean): GLSM Ratio = 1.018(90% CI, 0.9624 - 1.076); GLSM Ratio = 1.075(90% CI, 1.024 - 1.130); Area Under the Plasma Concentration-time Curve From Time 0 to t (AUC[0-t]) for Minzasolmin(Geometric Mean) = 5612 hour*nanograms per milliliter (h*ng/mL) (Geometric Coefficient of Variation, 34.6); Area Under the Plasma Concentration-time Curve From Time 0 to t (AUC[0-t]) for Minzasolmin(Geometric Mean): GLSM Ratio = 1.018(90% CI, 0.9624 - 1.076); GLSM Ratio = 1.075(90% CI, 1.024 - 1.130)

A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson's Disease

Phase 2; n=496; evaluation: not stated. Reported fields: Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I-III Sum Score at Day 0(Mean) = 34.0 score on a scale (Standard Deviation, 13.2); Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I-III Sum Score at Day 0(Mean) = 33.9 score on a scale (Standard Deviation, 16.4); -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Minzasolmin addresses Parkinson Disease. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2021-12-02	Novartis forms collaboration with UCB to jointly develop and market UCB-0599 for Parkinson's disease, with an additional option for UCB-7853 on a global scale.	Phase 1	US$150.0M upfront; US$1,500.0M milestones; US$1,650.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Compounds for use in the treatment of synucleinopathies”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO